Central Asia Metals shares drop as report points to shorter mine life at Sasa
proactiveinvestors.co.uk
Want to monitor PROK?
Get notified when price crosses targets, volume spikes, or RSI hits oversold
Create free account to monitor PROKprokidney (nasdaq: prok), a pioneer in the treatment of ckd through innovations in cellular therapy, was founded in 2015 after a decade of research. prokidney’s lead product candidate, react™ (renal autologous cell therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of ckd, but in some cases potentially drive meaningful improvement in kidney function. late-stage ckd, stage 3b - 4, is a key target for react™ therapy.